Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arrowhead Pharmaceuticals (ARWR) Depreciation and Depletion: 2017-2019

Historic Depreciation and Depletion for Arrowhead Pharmaceuticals (ARWR) over the last 1 years, with Jun 2019 value amounting to $578,342.

  • Arrowhead Pharmaceuticals' Depreciation and Depletion fell 23.00% to $578,342 in Q2 2019 from the same period last year, while for Jun 2019 it was $2.9 million, marking a year-over-year change of. This contributed to the annual value of $3.0 million for FY2018, which is 0.30% up from last year.
  • Latest data reveals that Arrowhead Pharmaceuticals reported Depreciation and Depletion of $578,342 as of Q2 2019, which was down 22.98% from $750,860 recorded in Q1 2019.
  • In the past 5 years, Arrowhead Pharmaceuticals' Depreciation and Depletion ranged from a high of $803,288 in Q3 2018 and a low of $578,342 during Q2 2019.
  • For the 3-year period, Arrowhead Pharmaceuticals' Depreciation and Depletion averaged around $725,756, with its median value being $750,860 (2019).
  • Per our database at Business Quant, Arrowhead Pharmaceuticals' Depreciation and Depletion rose by 5.05% in 2018 and then fell by 23.00% in 2019.
  • Over the past 3 years, Arrowhead Pharmaceuticals' Depreciation and Depletion (Quarterly) stood at $716,066 in 2017, then climbed by 5.05% to $752,245 in 2018, then fell by 23.00% to $578,342 in 2019.
  • Its last three reported values are $578,342 in Q2 2019, $750,860 for Q1 2019, and $752,245 during Q4 2018.